• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by OpGen Inc.

    5/16/25 4:39:39 PM ET
    $OPGN
    Medical Specialities
    Health Care
    Get the next $OPGN alert in real time by email
    NT 10-Q 1 opgen_nt10q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☐  Form 10-K    ☐  Form 20-F    ☐  Form 11-K    ☒  Form 10-Q    ☐  Form 10-D    ☐  Form N-CEN    ☐  Form N-CSR
       
     

    For Period Ended: March 31, 2025

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended: _______________________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

    PART I - REGISTRANT INFORMATION

     

    OpGen, Inc.

    Full Name of Registrant

     

     

     

    Former Name if Applicable

     

    23219 Stringtown Road, Suite 300

    Address of Principal Executive Office (Street and Number)

     

    Clarksburg, MD 20871

    City, State and Zip Code

     

     

     

     

     

     

    PART II - RULES 12B-25(B) AND (C)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-(b), the following should be completed. (Check box, if appropriate)

     

    ☒ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
       
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
       
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    OpGen, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “Form 10-Q”). The Company has determined that it is unable to file its Form 10-Q within the prescribed time period without unreasonable effort or expense. As previously reported, the Company scaled down operations in order to conserve cash and focus on the functions needed to pursue potential strategic alternatives. The Company therefore continues to operate with limited resources and personnel, and, as a result, experienced delays in compiling and finalizing accounting and financial documentation necessary for the Form 10-Q. Additionally, the Company is in the process of preparing its Annual Report on Form 10-K for the year ended December 31, 2024. Accordingly, the Company is unable, without unreasonable effort or expense, to timely file the Form 10-Q by the prescribed date.

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification.

     

      John Tan Honjian   (240)   808-8642
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☐ Yes   ☒ No

     

    Annual Report on Form 10-K for the year ended December 31, 2024.

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes   ☐ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The Company anticipates that significant changes in the results of operations will be reflected in the Company’s financial statements for the period ended March 31, 2025 as compared with the comparable period of 2024. The Company is still completing its financial close process for the year ended December 31, 2024 and quarter ended March 31, 2025, and, therefore, a reasonable quantitative estimate cannot be made at this time. 

     

    2

     

     

    OpGen, Inc.

    (Name of Registrant as specified in charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 16, 2025 By: /s/ John Tan Honjian
      Name: John Tan Honjian
      Title: Chairman and Chief Executive Officer

     

    3

    Get the next $OPGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OPGN
    Financials

    Live finance-specific insights

    See more
    • OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

      Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f

      8/10/23 4:15:00 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

      ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details       U.S. Dial-in Number:   1-877-704-4453       International Dial-in Number: 1-201-389-0920      Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6  Re

      8/3/23 7:30:00 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

      Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20

      5/15/23 4:15:00 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright resumed coverage on OpGen with a new price target

      HC Wainwright resumed coverage of OpGen with a rating of Buy and set a new price target of $4.00

      3/15/21 7:37:07 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • Alliance Global Partners reiterated coverage on OpGen with a new price target

      Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

      3/8/21 8:22:12 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • Alliance Global Partners reiterated coverage on OpGen with a new price target

      Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

      3/2/21 10:53:18 AM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

      ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all

      5/24/24 4:04:59 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Announced 1-for-10 Reverse Stock Split

      ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol "OPGN." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special

      5/16/24 7:00:00 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Provides Update on Business Operations and Strategic Opportunities

      ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd ("Camtech"), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's ("Curetis"), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings. In addition, the Company's subsidiary, Ares Genetics GmbH, sold all of its assets, including the ARESdb database and intellectual property portfolio to bioMerieux S.A., as part of Are

      4/29/24 4:05:00 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $OPGN
    SEC Filings

    See more

    $OPGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by OpGen Inc.

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      8/1/24 5:25:39 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      4/25/24 5:43:11 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      4/8/24 4:05:12 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - OPGEN INC (0001293818) (Filer)

      5/29/25 5:20:29 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form NT 10-Q filed by OpGen Inc.

      NT 10-Q - OPGEN INC (0001293818) (Filer)

      5/16/25 4:39:39 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form NT 10-K filed by OpGen Inc.

      NT 10-K - OPGEN INC (0001293818) (Filer)

      3/31/25 5:00:19 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Chief Technology Officer (CTO) Syed Mohd Syed Johan Bin was granted 9,709 shares (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      4/30/25 4:32:10 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Syed Mohd Syed Johan Bin

      3 - OPGEN INC (0001293818) (Issuer)

      4/30/25 4:30:31 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Director Wong Poh Yin Constance was granted 28,571 shares (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      12/19/24 4:34:06 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      12/10/24 12:32:18 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Large owner Aei Capital Ltd bought $11,130,140,980,409 worth of shares (5,245,603 units at $2,121,803.91) (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      10/8/24 6:51:09 PM ET
      $OPGN
      Medical Specialities
      Health Care